PhaseBio Pharmaceuticals, Inc

(NASDAQ:PHAS)

Latest On PhaseBio Pharmaceuticals, Inc (PHAS):

Date/Time Type Description Signal Details
2022-10-24 11:18 ESTNewsPhaseBio announces Chapter 11 filing; plans to sell lead assetN/A
2022-09-28 23:12 ESTNewsPhaseBio sinks ~67% after getting transfer notice for lead drug bentracimab's businessN/A
2022-08-12 23:41 ESTNewsPhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29MN/A
2022-05-16 17:30 ESTNewsPhaseBio Pharmaceuticals GAAP EPS of -$0.23 beats by $0.43N/A
2022-05-16 17:30 ESTNewsPhaseBio to seek FDA approval for clotting agent in 4Q 2022N/A
2022-04-04 21:51 ESTNewsPhaseBio reports full results of phase 2b trial of bentracimab to reverse ticagrelor's antiplatelet activityN/A
2022-03-24 20:54 ESTNewsPhaseBio Pharmaceuticals GAAP EPS of -$0.90 misses by $0.32, revenue of $0.58M misses by $1.39MN/A
2022-03-08 18:19 ESTNewsPhaseBio completes campaign for commercial-scale manufacturing runs for bentracimabN/A
2021-12-22 02:29 ESTNewsPhaseBio ends mid-stage trial of pulmonary arterial hypertension DRUG due to COVID impactsN/A
2021-11-18 21:04 ESTNewsPhaseBio Pharmaceuticals appoints Jonathan Birchall as Chief Commercial OfficerN/A
2021-11-16 06:11 ESTNewsPhaseBio announces pivotal data for anti-platelet agentN/A
2021-11-11 11:22 ESTNewsPhaseBio Pharmaceuticals EPS misses by $0.05, misses on revenueN/A
2021-11-03 17:17 ESTNewsPhaseBio Pharmaceuticals' bentracimab treatment meets main goal in mid-stage trialN/A
2021-10-12 11:31 ESTNewsWarning: PHAS is at high risk of performing badlyN/A
2021-10-06 15:17 ESTNewsPHAS is at high risk of performing badlyN/A
2021-10-06 15:02 ESTNewsPhaseBio to present bentracimab phase 3 trial data in November; eyes BLA filing by mid '22N/A
2021-09-28 00:01 ESTNewsWarning: PHAS has been downgraded to Very BearishN/A
2021-09-27 23:47 ESTNewsOther biotechs with PAH candidates benefitting from talk of Acceleron acquistionN/A
2021-09-23 09:54 ESTNewsWarning: PHAS has been downgraded to Very Bearish.N/A
2021-08-12 22:44 ESTNewsPhaseBio Pharmaceuticals EPS misses by $0.14, beats on revenueN/A
2021-08-10 09:46 ESTNewsPhaseBio Pharmaceuticals gets IND approval for bentracimab in ChinaN/A
2021-07-21 19:34 ESTNewsPhaseBio shares surge after inking exclusive license agreement for bentracimabN/A
2021-04-22 20:39 ESTNewsPhaseBio Pharmaceuticals (PHAS) Investor Presentation - SlideshowN/A
2021-04-18 21:47 ESTNewsRevisiting PhaseBioN/A
2021-03-19 00:42 ESTNewsPhaseBio shares down on equity raiseN/A
2021-03-18 03:56 ESTNewsPhaseBio initiates stock offering; shares down 12% after-hours (updated)N/A
2021-03-17 21:35 ESTAnalyst RatingThe Analyst Target Price has increased from $13.5 to $13.75.Buy
2021-03-17 13:29 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 06:08 ESTNewsPhaseBio Pharmaceuticals EPS misses by $0.36N/A
2021-03-17 06:04 ESTNewsPhaseBio Pharmaceuticals gains 14% after Needham raises PT to street high (updated)N/A
2021-03-16 21:44 ESTEarnings EstimateAn EPS average of -$0.64 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-16 21:44 ESTEarnings EstimateAn EPS average of -$2.36 is estimated for the 2022 year.Sell
2021-03-11 12:27 ESTNewsPhaseBio Pharma inks supply deal for development of bentracimabN/A
2021-02-10 16:48 ESTNewsPhaseBio shares spike 22% in afternoon tradingN/A
2021-01-28 11:45 ESTNewsUnited Therapeutics’ Tyvaso DPI meets primary objectiveN/A
2021-01-27 19:41 ESTNewsPhaseBio presents Phase 1/2 data for Pemziviptadil in pulmonary arterial hypertensionN/A
2021-01-21 13:09 ESTNewsPhaseBio: Interesting Platform With Additive Value, Low On CashN/A
2021-01-05 12:31 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.25 to $13.5.Neutral
2020-11-26 21:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 09:28 ESTNewsAcceleron's sotatercept shows positive action in mid-stage pulmonary arterial hypertension studiesN/A
2020-11-13 13:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 13:02 ESTEarnings EstimateAn EPS average of -$0.67 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-13 06:48 ESTNewsPhaseBio Pharmaceuticals EPS misses by $0.15N/A
2020-11-08 00:36 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:49 ESTFinancialsCompany financials have been released.Neutral
2020-10-24 06:58 ESTNewsPhaseBio pulls the plug on pemziviptadil COVID-19 studyN/A
2020-10-06 19:56 ESTNewsPhaseBio initiates late-stage study of lead drug bentracimab in CanadaN/A
2020-10-05 21:27 ESTInsider TradeSusan Elizabeth Arnold has directly acquired 5,423 shares and currently holds 13,152 shares.Buy
2020-09-26 13:44 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:50 ESTFinancialsCompany financials have been released.Neutral

About PhaseBio Pharmaceuticals, Inc (PHAS):

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is PB2452, a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients experiencing uncontrolled bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.

PHAS Quotes by TradingView

See Advanced Chart

General

  • Name PhaseBio Pharmaceuticals, Inc
  • Symbol PHAS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 50
  • Fiscal Year EndDecember
  • IPO Date2018-10-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://phasebio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 103.44
  • Price/Book (Most Recent Quarter) 26.18
  • Enterprise Value Revenue 83.17
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.75
  • Next Year EPS Estimate -$2.45
  • Next Quarter EPS Estimate -$0.72
  • Operating Margin -26518%
  • Return on Assets -80%
  • Return on Equity -567%
  • Revenue 320000
  • Earnings Per Share -$1.62
  • Revenue Per Share $0.01
  • Gross Profit -71768000
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 126.9 million
  • EBITDA -29400000
  • Analyst Target Price $13.75
  • Book Value Per Share $0.15
View More

Share Statistics

  • Shares Outstanding 29.44 million
  • Shares Float 15.54 million
  • % Held by Insiders 1118%
  • % Held by Institutions 68.74%
  • Shares Short 3.14 million
  • Shares Short Prior Month 3.13 million
  • Short Ratio 8.57
  • Short % of Float 24%
  • Short % of Shares Outstanding 11%
View More

Technicals

  • Beta 1.81
  • 52 Week High $6.35
  • 52 Week Low $2.6
  • 50 Day Moving Average 4.21
  • 200 Day Moving Average 3.77
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

PhaseBio Pharmaceuticals, Inc (PHAS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

PhaseBio Pharmaceuticals, Inc (PHAS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-15$N/A-$1.03-$0.70-47.14%
2020-09-302020-11-12$N/A-$0.86-$0.83-3.03%
2020-06-302020-08-11$N/A-$0.98-$0.52-89.67%
2020-03-312020-05-12$320000-$0.52-$0.42-23.46%
2019-12-312020-03-30$N/A-$0.40-$0.40-1.27%
2019-09-302019-11-14$241000-$0.40-$0.36-9.83%
2019-06-302019-08-13$703000-$0.33-$0.330.69%
2019-03-312019-05-09$653000-$0.30-$0.4126.72%
2018-12-312019-03-26$257000-$0.46-$0.29-57.95%
2018-09-302018-11-29$411000-$10.45-$0.46-2190.66%

PhaseBio Pharmaceuticals, Inc (PHAS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A 11.45 million N/A
Income Before Tax N/A N/A N/A -14.91 million N/A
Selling General Administrative N/A N/A N/A 3.16 million N/A
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A -14.47 million N/A
Operating Income N/A N/A N/A -14.29 million N/A
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A 320000 N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A -450000 N/A
Net Income From Continuing Operations N/A N/A N/A -14.91 million N/A
Net Income Applicable to Common Shares -30.38 million -25.14 million -28.14 million N/A -11.33 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -658000 N/A N/A
Change to Liabilities -5.42 million 5.01 million N/A 916000 -1.36 million
Total Cash Flow from Investing Activities -178000 -521000 N/A -136000 -395000
Net Borrowings -1.36 million N/A N/A 5 million N/A
Total Cash Flow from Financial Activities N/A N/A 9.9 million N/A 64000
Change to Operating Activities 1.9 million 3.63 million N/A -2.04 million 3.27 million
Change in Cash N/A N/A -14.58 million N/A -8.57 million
Total Cash from Operating Activities -15.83 million -8.96 million -23.83 million -12.49 million -8.24 million
Depreciation N/A N/A 54000 N/A 50000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 598000
Other Cash Flow from Financing Activities 1.2 million 2.59 million N/A -145000 N/A
Change to Net Income 14.02 million 9.59 million N/A 568000 591000
Capital Expenditures N/A N/A 658000 N/A 395000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A 23.37 million N/A
Total Stockholder Equity N/A N/A N/A 53.49 million N/A
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets N/A N/A N/A 76.86 million N/A
Common Stock 29000 29000 29000 N/A 29000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -260.72 million -230.35 million -205.21 million -177.06 million -162.16 million
Other Liabilities 52.28 million 32.7 million 15.07 million N/A 203000
Other Assets 57000 57000 57000 N/A 32000
Cash N/A N/A N/A 59.44 million N/A
Total Current Liabilities 14.96 million 11.37 million N/A 7.5 million N/A
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 10.15 million 8.2 million 7.01 million N/A 3.64 million
Total Current Assets 40.15 million 49.95 million N/A 72.54 million N/A
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets -25.2 million 4.35 million 26.39 million N/A 59.98 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A 11.06 million N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 3.67 million 2.12 million N/A 1.92 million N/A

PhaseBio Pharmaceuticals, Inc (PHAS) Chart:

PhaseBio Pharmaceuticals, Inc (PHAS) News:

Below you will find a list of latest news for PhaseBio Pharmaceuticals, Inc (PHAS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

PhaseBio Pharmaceuticals, Inc (PHAS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest PHAS Trades:

Date Shares Price
Jun 13, 2022 6:33 PM EST100$0.6235
Jun 13, 2022 6:50 PM EST100$0.6304
Jun 13, 2022 7:00 PM EST100$0.6304
Jun 13, 2022 7:30 PM EST100$0.6302
Jun 13, 2022 7:59 PM EST194$0.6309

PhaseBio Pharmaceuticals, Inc (PHAS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000069/0001169245-20-000069-index.htm
2019-04-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1169245/000000000019006717/0000000000-19-006717-index.htm
2020-01-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1169245/000000000020000056/0000000000-20-000056-index.htm
2018-11-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1169245/000090221918000533/0000902219-18-000533-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1169245/000090221919000358/0000902219-19-000358-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1169245/000090221920000138/0000902219-20-000138-index.htm
2019-01-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1169245/000090445419000079/0000904454-19-000079-index.htm
2020-01-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1169245/000090445420000049/0000904454-20-000049-index.htm
2019-03-29DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1169245/000095012319002942/0000950123-19-002942-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000003/0001169245-20-000003-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000005/0001169245-20-000005-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000007/0001169245-20-000007-index.htm
2020-02-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000010/0001169245-20-000010-index.htm
2020-02-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000012/0001169245-20-000012-index.htm
2020-02-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000014/0001169245-20-000014-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000016/0001169245-20-000016-index.htm
2020-02-143Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000018/0001169245-20-000018-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000027/0001169245-20-000027-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000028/0001169245-20-000028-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000029/0001169245-20-000029-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000030/0001169245-20-000030-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000031/0001169245-20-000031-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000032/0001169245-20-000032-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000033/0001169245-20-000033-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000034/0001169245-20-000034-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000036/0001169245-20-000036-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000038/0001169245-20-000038-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000042/0001169245-20-000042-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1169245/000116924520000043/0001169245-20-000043-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000044/0001169245-20-000044-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000047/0001169245-20-000047-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000049/0001169245-20-000049-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1169245/000116924520000051/0001169245-20-000051-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000053/0001169245-20-000053-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000055/0001169245-20-000055-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000057/0001169245-20-000057-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000059/0001169245-20-000059-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000061/0001169245-20-000061-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000063/0001169245-20-000063-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000065/0001169245-20-000065-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000067/0001169245-20-000067-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000069/0001169245-20-000069-index.htm
2020-07-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000071/0001169245-20-000071-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000073/0001169245-20-000073-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1169245/000116924520000075/0001169245-20-000075-index.htm
2020-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000077/0001169245-20-000077-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000079/0001169245-20-000079-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000081/0001169245-20-000081-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000083/0001169245-20-000083-index.htm
2020-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000116924520000086/0001169245-20-000086-index.htm
2019-04-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1169245/000117266119001077/0001172661-19-001077-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1169245/000117266120000738/0001172661-20-000738-index.htm
2018-11-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1169245/000119312518322513/0001193125-18-322513-index.htm
2019-04-09S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1169245/000119312519101668/0001193125-19-101668-index.htm
2019-04-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1169245/000119312519101687/0001193125-19-101687-index.htm
2019-04-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1169245/000119312519101693/0001193125-19-101693-index.htm
2019-04-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1169245/000119312519102582/0001193125-19-102582-index.htm
2019-04-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1169245/000119312519102587/0001193125-19-102587-index.htm
2019-04-11S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1169245/000119312519104225/0001193125-19-104225-index.htm
2019-04-12424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1169245/000119312519105228/0001193125-19-105228-index.htm
2019-07-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1169245/000119312519205450/0001193125-19-205450-index.htm
2019-12-27S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1169245/000119312519324990/0001193125-19-324990-index.htm
2020-01-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1169245/000119312520002161/0001193125-20-002161-index.htm
2018-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118061125/0001209191-18-061125-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118061982/0001209191-18-061982-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118061987/0001209191-18-061987-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118061990/0001209191-18-061990-index.htm
2018-12-134/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118062480/0001209191-18-062480-index.htm
2018-12-173/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118062929/0001209191-18-062929-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118062931/0001209191-18-062931-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118062934/0001209191-18-062934-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118062939/0001209191-18-062939-index.htm
2018-12-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118062941/0001209191-18-062941-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919118062943/0001209191-18-062943-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015011/0001209191-19-015011-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015012/0001209191-19-015012-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015018/0001209191-19-015018-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015025/0001209191-19-015025-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015032/0001209191-19-015032-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015036/0001209191-19-015036-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015044/0001209191-19-015044-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015055/0001209191-19-015055-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015067/0001209191-19-015067-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015076/0001209191-19-015076-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015085/0001209191-19-015085-index.htm
2019-03-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015094/0001209191-19-015094-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015098/0001209191-19-015098-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119015112/0001209191-19-015112-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119029351/0001209191-19-029351-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119029352/0001209191-19-029352-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119029355/0001209191-19-029355-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119029356/0001209191-19-029356-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119029357/0001209191-19-029357-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119029358/0001209191-19-029358-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119029365/0001209191-19-029365-index.htm
2019-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119031833/0001209191-19-031833-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119032659/0001209191-19-032659-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/0001209191-19-038324-index.htm
2019-07-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/0001209191-19-041112-index.htm
2019-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119047182/0001209191-19-047182-index.htm
2019-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119049010/0001209191-19-049010-index.htm
2019-10-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119052719/0001209191-19-052719-index.htm
2019-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1169245/000120919119052721/0001209191-19-052721-index.htm
2018-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459018030285/0001564590-18-030285-index.htm
2018-11-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1169245/000156459018030291/0001564590-18-030291-index.htm
2018-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459018030995/0001564590-18-030995-index.htm
2019-01-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019001152/0001564590-19-001152-index.htm
2019-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019005930/0001564590-19-005930-index.htm
2019-03-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019008789/0001564590-19-008789-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019009339/0001564590-19-009339-index.htm
2019-03-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1169245/000156459019009342/0001564590-19-009342-index.htm
2019-03-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1169245/000156459019009364/0001564590-19-009364-index.htm
2019-04-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019010797/0001564590-19-010797-index.htm
2019-04-05DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1169245/000156459019010914/0001564590-19-010914-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019011026/0001564590-19-011026-index.htm
2019-04-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019011067/0001564590-19-011067-index.htm
2019-04-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019011174/0001564590-19-011174-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019017970/0001564590-19-017970-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1169245/000156459019017982/0001564590-19-017982-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019018647/0001564590-19-018647-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019022659/0001564590-19-022659-index.htm
2019-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019024169/0001564590-19-024169-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019031786/0001564590-19-031786-index.htm
2019-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1169245/000156459019031993/0001564590-19-031993-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019031995/0001564590-19-031995-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019035318/0001564590-19-035318-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019036902/0001564590-19-036902-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1169245/000156459019043372/0001564590-19-043372-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1169245/000156459019043373/0001564590-19-043373-index.htm
2019-04-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1169245/999999999519000684/9999999995-19-000684-index.htm
2020-01-08EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1169245/999999999520000039/9999999995-20-000039-index.htm

PhaseBio Pharmaceuticals, Inc (PHAS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of PhaseBio Pharmaceuticals, Inc (PHAS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1118%
Institutional Ownership: 6874%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-12-17Nancy J HutsonDirectorBuy1,000.004.464,460.001,000.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118062934/0001209191-18-062934-index.htm
2019-09-06Jonathan P MowChief Executive OfficerBuy19,000.001.2423,560.00109,243.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119049010/0001209191-19-049010-index.htm
2020-08-21Jonathan P MowChief Executive OfficerBuy10,000.001.2412,400.00119,243.00https://www.sec.gov/Archives/edgar/data/1169245/000116924520000079/0001169245-20-000079-index.htm
2020-10-01Susan Elizabeth ArnoldVP, Preclinical and ChemBuy5,423.001.156,236.4513,152.00https://www.sec.gov/Archives/edgar/data/1169245/000116924520000081/0001169245-20-000081-index.htm
2018-12-11Michael YorkVP, Corporate DevelopmentBuy1,500.003.885,820.001,500.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118061990/0001209191-18-061990-index.htm
2018-12-04Clay ThorpDirectorBuy4,000.003.1312,520.0015,799.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118061125/0001209191-18-061125-index.htm
2019-07-01Clay ThorpDirectorSell180.0014.002,520.00162,890.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/0001209191-19-041112-index.htm
2019-06-18Clay ThorpDirectorSell25.0014.00350.00163,074.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/0001209191-19-038324-index.htm
2019-07-01Clay ThorpDirectorSell2,014.0014.0028,196.001,818,638.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/0001209191-19-041112-index.htm
2019-06-18Clay ThorpDirectorSell277.0014.003,878.001,820,656.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/0001209191-19-038324-index.htm
2019-05-22John P SharpCFO and SecretaryBuy15,000.001.6925,350.0020,000.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119032659/0001209191-19-032659-index.htm
2019-08-21John P SharpCFO and SecretaryBuy10,000.001.6916,900.0030,000.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119047182/0001209191-19-047182-index.htm
2019-08-21John P SharpCFO and SecretaryBuy5,000.001.447,200.0035,000.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119047182/0001209191-19-047182-index.htm
2020-08-14John P SharpChief Financial OfficerBuy5,000.001.698,450.0040,000.00https://www.sec.gov/Archives/edgar/data/1169245/000116924520000077/0001169245-20-000077-index.htm
2019-07-01Clay ThorpDirectorSell459.0014.006,426.00415,959.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/0001209191-19-041112-index.htm
2019-06-18Clay ThorpDirectorSell63.0014.00882.00416,418.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/0001209191-19-038324-index.htm
2018-12-07John P SharpCFO and SecretaryBuy5,000.003.8419,200.005,000.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118061987/0001209191-18-061987-index.htm
2018-12-07Jonathan P MowChief Executive OfficerBuy2,200.003.888,536.0050,899.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118061982/0001209191-18-061982-index.htm
2018-12-13Jonathan P MowChief Executive OfficerBuy1,000.003.693,690.0051,199.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118062931/0001209191-18-062931-index.htm
2018-12-10Jonathan P MowChief Executive OfficerBuy800.003.853,080.0051,699.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118061982/0001209191-18-061982-index.htm
2019-07-01Clay ThorpDirectorSell255.0014.003,570.0052,397.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119041112/0001209191-19-041112-index.htm
2019-06-18Clay ThorpDirectorSell35.0014.00490.0052,655.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119038324/0001209191-19-038324-index.htm
2019-05-17Jonathan P MowChief Executive OfficerBuy19,913.002.2745,202.5171,112.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119031833/0001209191-19-031833-index.htm
2018-12-13David James BallanceVP, Research and Sci. AffairsBuy1,000.003.943,940.007,600.00https://www.sec.gov/Archives/edgar/data/1169245/000120919118062939/0001209191-18-062939-index.htm
2019-05-20Jonathan P MowChief Executive OfficerBuy19,131.001.2423,722.4490,243.00https://www.sec.gov/Archives/edgar/data/1169245/000120919119031833/0001209191-19-031833-index.htm